These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10509530)

  • 21. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
    Miners J
    Pharmacogenetics; 2002 Mar; 12(2):91-2. PubMed ID: 11875362
    [No Abstract]   [Full Text] [Related]  

  • 22. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.
    London SJ; Daly AK; Leathart JB; Navidi WC; Idle JR
    Pharmacogenetics; 1996 Dec; 6(6):527-33. PubMed ID: 9014202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic modulation of oral anticoagulation with warfarin.
    Margaglione M; Colaizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di Minno G
    Thromb Haemost; 2000 Nov; 84(5):775-8. PubMed ID: 11127854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.
    Leung AY; Chow HC; Kwong YL; Lie AK; Fung AT; Chow WH; Yip AS; Liang R
    Blood; 2001 Oct; 98(8):2584-7. PubMed ID: 11588061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.
    Yoon YR; Shon JH; Kim MK; Lim YC; Lee HR; Park JY; Cha IJ; Shin JG
    Br J Clin Pharmacol; 2001 Mar; 51(3):277-80. PubMed ID: 11298075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.
    Thijssen HH; Verkooijen IW; Frank HL
    Pharmacogenetics; 2000 Nov; 10(8):757-60. PubMed ID: 11186138
    [No Abstract]   [Full Text] [Related]  

  • 27. Avoiding overanticoagulation: pharmacogenomics or pragmatism?
    Baglin T
    Thromb Haemost; 2001 May; 85(5):945-6. PubMed ID: 11372698
    [No Abstract]   [Full Text] [Related]  

  • 28. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.
    Henne KR; Gaedigk A; Gupta G; Leeder JS; Rettie AE
    J Chromatogr B Biomed Sci Appl; 1998 Jun; 710(1-2):143-8. PubMed ID: 9686881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.
    Hanatani T; Fukuda T; Ikeda M; Imaoka S; Hiroi T; Funae Y; Azuma J
    Pharmacogenomics J; 2001; 1(4):288-92. PubMed ID: 11908770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines.
    Yilmaz N; Erbağci AB; Aynacioğlu AS
    Acta Biochim Pol; 2001; 48(3):775-82. PubMed ID: 11833786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green.
    Hiratsuka M; Agatsuma Y; Mizugaki M
    Mol Genet Metab; 1999 Nov; 68(3):357-62. PubMed ID: 10562462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
    Lee CR; Goldstein JA; Pieper JA
    Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
    Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
    Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphism induced sensitivity to warfarin: a review of the literature.
    Palkimas MP; Skinner HM; Gandhi PJ; Gardner AJ
    J Thromb Thrombolysis; 2003 Jun; 15(3):205-12. PubMed ID: 14739630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.
    Imai J; Ieiri I; Mamiya K; Miyahara S; Furuumi H; Nanba E; Yamane M; Fukumaki Y; Ninomiya H; Tashiro N; Otsubo K; Higuchi S
    Pharmacogenetics; 2000 Feb; 10(1):85-9. PubMed ID: 10739176
    [No Abstract]   [Full Text] [Related]  

  • 36. Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk.
    García-Martín E; Martínez C; Ladero JM; Gamito FJ; Rodriguez-Lescure A; Agúndez JA
    Cancer Lett; 2002 Jun; 180(1):41-6. PubMed ID: 11911968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.
    García-Martín E; Martínez C; Ladero JM; Gamito FJ; Agúndez JA
    Eur J Clin Pharmacol; 2001 Apr; 57(1):47-9. PubMed ID: 11372590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.
    Hermida J; Zarza J; Alberca I; Montes R; López ML; Molina E; Rocha E
    Blood; 2002 Jun; 99(11):4237-9. PubMed ID: 12010835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.
    Scordo MG; Aklillu E; Yasar U; Dahl ML; Spina E; Ingelman-Sundberg M
    Br J Clin Pharmacol; 2001 Oct; 52(4):447-50. PubMed ID: 11678789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
    Borlak J; Thum T
    Clin Chem; 2002 Sep; 48(9):1592-4. PubMed ID: 12194942
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.